For the Inventor, By the Inventor

Enter assignee name

Waltham, MA, United States of America

Dyne Therapeutics, Inc.

USPTO Granted Patents = 59

Trademarks = 6

Forward Citations = 1,132

Loading Chart...

Loading Chart...

16 inventors (with patents filed for the assignee):

Romesh R Subramanian (59 out of 77 patents)

Mohammed T Qatanani (59 out of 61 patents)

Timothy Weeden (58 out of 60 patents)

4. Cody A Desjardins (39 out of 40 patents)

5. Brendan Quinn (29 out of 29 patents)

6. John Najim (27 out of 27 patents)

7. Scott Hilderbrand (4 out of 5 patents)

8. Stefano Zanotti (2 out of 2 patents)

9. Kim Tang (2 out of 2 patents)

10. Sean Spring (1 out of 1 patent)

11. Peiyi Shen (1 out of 1 patent)

12. Jason P Rhodes (1 out of 1 patent)

13. Timothy Weeden (1 out of 2 patents)

14. John Najim (1 out of 1 patent)

15. Stefano Zanotti (1 out of 2 patents)

Core Competencies:

Muscle Targeting Complexes

Anti-Transferrin Receptor Antibody

Oligonucleotide Delivery

Myotonic Dystrophy

Dystrophinopathies

Facioscapulohumeral Muscular Dystrophy

Exon Skipping

Therapeutic Formulations

59 patents: Sort by Forward Citations

1. 12746290 - MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY (2026-09-29),

2. 12742007 - MUSCLE-TARGETING COMPLEXES AND USES THEREOF (2026-09-22),

3. 12734246 - ANTI-TRANSFERRIN RECEPTOR (TFR) ANTIBODY, ENCODING NUCLEIC ACID THEREOF AND METHOD OF USE THEREOF TO DELIVER AN OLIGONUCLEOTIDE TO A SUBJECT (2026-09-15),

4. 12697394 - MUSCLE TARGETING COMPLEXES AND FORMULATIONS FOR TREATING MYOTONIC DYSTROPHY (2026-08-04),

5. 12662545 - Complexes Comprising An Anti-Transferrin Receptor Antibody Linked To An Oligonucleotide And Method Of Delivering Oligonucleotide To A Subject (2026-06-23),

6. 12629426 - Muscle targeting complexes and uses thereof for treating dystrophinopathies (2026-05-19),

7. 12624120 - ANTI-TRANSFERRIN RECEPTOR (TFR) ANTIBODY AND USES THEREOF (2026-05-12),

8. 12460011 - Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering an oligonucleotide to a subject (2025-11-04),

9. 12440575 - Muscle targeting complexes and uses thereof for treating dystrophinopathies (2025-10-14),

10. 12440574 - Muscle targeting complexes and formulations for treating myotonic dystrophy (2025-10-14),

11. 12428487 - Complexes comprising an anti-transferrin receptor antibody linked to an oligonicleotide and method of delivering oligonucleotide to a subject (2025-09-30),

12. 12403203 - Muscle targeting complexes and uses thereof for treating dystrophinopathies (2025-09-02),

13. 12397062 - Muscle targeting complexes and uses thereof for treating dystrophinopathies (2025-08-26),

14. 12370264 - Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject (2025-07-29),

15. 12357703 - Muscle-targeting complexes comprising an anti-transferin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping (2025-07-15),

Company Overview

Dyne Therapeutics, Inc., based in Waltham, MA, specializes in developing innovative therapies targeting muscle diseases. The company focuses on Muscle Targeting Complexes, which enhance the delivery of therapeutic oligonucleotides to muscle tissues. Its research encompasses various conditions, including myotonic dystrophy, dystrophinopathies, and facioscapulohumeral muscular dystrophy. By leveraging advanced technologies such as anti-transferrin receptor antibodies and exon skipping, Dyne aims to create effective treatment options for patients with debilitating muscle disorders.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

59 Patents

#29 in Waltham, MA

#343 in Massachusetts

#6,071 in US

#12,232 in the World

Waltham, MA, United States of America

Dyne Therapeutics, Inc.

Forward Citations = 1,132

16 inventors:

Romesh R Subramanian (59 out of 77 patents)

Mohammed T Qatanani (59 out of 61 patents)

Timothy Weeden (58 out of 60 patents)

4. Cody A Desjardins (39 out of 40 patents)

5. Brendan Quinn (29 out of 29 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Dyne Therapeutics, Inc.. Retrieved from https://idiyas.com/company/dyne-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…